Zealand Pharma A/S, A Biotechnology Company Focused On The Discovery, Development And Commercialization Of Innovative Peptide-Based Medicines, Announced Completion Of Patient Enrollment In The Second Phase 3-Trial, 17103, Of Dasiglucagon For The Treatment Of Congenital Hyperinsulinism (Chi) In Neonates Up To 12 Months Old. This Phase 3 Study Is The Last In The Program Which Constitute The Largest Clinical Development Programme Ever Conducted In Chi.Chi Is The Most Frequent Cause Of Severe And Persistent Hypoglycemia. It Starts As Early As The Neonatal Period And Profoundly Affects Those Children And Their Families Through Infancy And Teenage Years. It Is Characterized By An Excessive And Uncontrolled Insulin Secretion Triggering Recurrent Episodes Of Profound Hypoglycemia Which Require Constant Surveillance And Rapid And Intensive Interventions To Prevent Neurological Sequelae.
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions! Learn More!